Disposition in mice of 7-hydroxystaurosporine,a protein kinase inhibitor with antitumor activity |
| |
Authors: | Donald L. Hill Kathleen F. Tillery Lucy M. Rose Claude F. Posey |
| |
Affiliation: | (1) Southern Research Institute, P.O. Box 55305, 35255-5305 Birmingham, AL, USA |
| |
Abstract: | UCN-01, a hydroxylated derivative of staurosporine, was selected for study because of its promising antitumor activity. For mice dosed intravenously, subcutaneously, or by oral gavage with this compound, the maximum tolerated doses (MTD) were 20, 10, and >100 mg/kg, respectively. UCN-01 was stable in mouse and dog plasma, but in human plasma it was converted to a metabolite in a process not inhibited by standard protease and esterase inhibitors. Following n intravenous dose of 10 mg/kg UCN-01, the half-lives for the initial (t1/2 ) and terminal (t1/2 ) exponential phases of elimination were 10 and 85 min, respectively; the area under the plasma concentration-time curve (AUC value) was 117 g min ml–1. In mice dosed by oral gavage with 10 mg/kg, the calculated value for the half-life of the elimination phase was 150 min. The AUC value was 15 g min ml–1, giving a value for bioavailability of 13%. After subcutaneous dosing with 10 mg/kg, the calculated values for half-lives for the distribution and elimination phases were 23 and 130 min, respectively; the AUC value was 113 g min ml–1. Since this value is equivalent to that obtained for intravenous dosing, administration of UCN-01 by the subcutaneous route may be an alternative to intravenous dosing in preclinical and clinical trials.This work was supported by contract NO1-CM-27710 (National Cancer Institute, National Institutes of Health, Department of Health and Human Services) |
| |
Keywords: | Disposition 7-Hydroxystaurosporine Protein kinase |
本文献已被 SpringerLink 等数据库收录! |
|